For moderate to severe Crohn's disease (CD) in adult TNFi-IR patients.1
For moderate to severe ulcerative colitis (UC) in adult TNFi-IR patients.1
RINVOQ IS A
RINVOQ is an oral small molecule that inhibits the JAK-STAT signalling pathway, utilized by pro-inflammatory cytokines.1,2
The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.
IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor
Crohn’s Disease (CD):
AN INFLAMMATORY CONDITION OF THE GI TRACT
CD is an inflammatory condition with genetic, immunologic, and environmental influences and is characterized by abdominal pain, diarrhea, and fatigue.3
Crohn’s Disease (CD):
Several key cytokines are thought to use signaling networks such as the JAK-STAT Pathway.
Overexpression of these key cytokines can lead to excess inflammation and may contribute to the signs and symptoms of CD.4,5
CYTOKINES
Pro-inflammatory Cytokines Involved in CD Pathogenesis1,5
INSIDE THE CELL
The pro-inflammatory cytokines that activate the JAK-STAT pathways contribute to the pathogenesis of CD through their role in inflammation. However, these same cytokines are also important for general cellular functions such as immune system modulation, cell growth, and hematopoiesis.2,5
Mechanism of Action
HOW RINVOQ WORKS
RINVOQ targets JAK, affecting the JAK-STAT pathway inside the cell, which is linked to the signaling of pro-inflammatory cytokines.1,2
Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK1 and JAK2 relative to JAK3 and TYK2.1,2
The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not known.
INHIBITORY POTENCY
ACROSS CYTOKINES
By binding to JAK, RINVOQ prevents the phosphorylation and activation of STATs, disrupting the pro-inflammatory signaling cascade.1,2
The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not known.
ONCE DAILY
Images not reflective of actual pill size
In clinical trials, RINVOQ has been shown to provide significant clinical remission* and endoscopic response† at Weeks 12 and 52 for moderate to severe CD in adult TNFi-IR patients.1
RECOMMENDED MAINTENANCE DOSING
A maintenance dose of 30 mg may be considered for patients with refractory, severe, or extensive disease. Discontinue RINVOQ if an adequate therapeutic response is not achieved with the 30 mg dose.
*Clinical remission was defined as Crohn's disease activity index (CDAI) <150 points.
†Endoscopic response was defined as a decrease in SES-CD >50% from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease, based on central reading. The sections evaluated on endoscopy are the: rectum, sigmoid and left colon, transverse colon, right colon and ileum (per SES-CD assessment).
Mechanism of Disease
THE ROLE OF THE
JAK-STAT PATHWAY4,5
Pro-inflammatory cytokines utilize signaling pathways—such as the JAK-STAT pathway—to communicate with the cell nucleus.
The cytokine binds to a specific receptor on the cell surface that modulates JAK-mediated signaling.
The receptor spans the cell's membrane
and cytokine binding
triggers JAK
activation inside the cell.
The activated JAK then mobilizes STATs,
which transmit the
signal into the cell nucleus.
This signaling contributes to the
inflammatory response in CD.
RINVOQ IS A
By targeting JAK, RINVOQ is thought to block the recruitment, phosphorylation, and activation of STATs and inhibit the pro-inflammatory processes associated with the JAK-STAT pathway.1,4,5
The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.
INTERESTED IN LEARNING
ABOUT THE SAFETY DATA?
See RINVOQ’s safety data
across clinical trials
